GlassScriptPhysician profile
Ikemefuna Akusoba
NPI 1740544998
$2,907.39
in general payments reported to CMS, 2019-2025
7 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.50 · 2022: $12.60 · 2023: $224 · 2024: $2,059 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,510 · Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,510.06 |
| Food and Beverage | $1,321.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,467.50 | 2024-2025 | Apollo Esg Nxt System, Apollo Esg System |
| Medical Device Business Services, INC. | $579.88 | 2024-2025 | Linx Reflux Management System |
| Ethicon US, LLC | $435.23 | 2024-2025 | Linx Reflux Management System, Echelon Circular |
| Medtronic, INC. | $151.16 | 2022-2023 | Sonicision, Signia |
| Lilly USA, LLC | $124.74 | 2024 | Zepbound |
| Olympus America INC. | $85.38 | 2023 | 4k Cable 8.5m |
| Covidien LP | $63.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikemefuna Akusoba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.